Cytosorbents receives Nasdaq minimum-value notice, given until December 28 to comply
CytoSorbents Corporation received a notice from Nasdaq on June 29, 2026 that its Market Value of Listed Securities fell below the $35 million minimum required under Nasdaq Listing Rule 5550(b)(2). The company has 180 calendar days, until December 28, 2026, to regain compliance by achieving a market value of at least $35 million for 10 consecutive business days. The company is evaluating options including increasing stockholders' equity to at least $2.5 million; failure to comply will result in a delisting notice, which the company may appeal.
Key facts
- Compliance Date: December 28, 2026
- Minimum Market Value of Listed Securities requirement: $35 million
- Grace period: 180 calendar days from June 29, 2026
- Required consecutive business days at compliance level: 10
- Alternative compliance option: stockholders' equity of at least $2.5 million
- Nasdaq Listing Rule 5550(b)(2) and 5810(c)(3)(C)
Why it matters
CytoSorbents has a defined cure period to restore its market capitalization above the Nasdaq minimum; failure to do so will trigger a delisting determination, though the company retains the right to appeal.
Share
Derived from 8-K filed 2026-07-06. Not investment advice. View the source filing on SEC.gov →